METHOTREXATE SODIUM - Generic Drug Details

What are the generic sources for methotrexate sodium and what is the scope of freedom to operate?

Methotrexate sodium is the generic ingredient in twelve branded drugs marketed by Abic, Pharmacia And Upjohn, Hospira, Fresenius Kabi Usa, Abraxis Pharm, Hikma, Norbrook, Pharmachemie Usa, Accord Hlthcare, Eugia Pharma Speclts, Extrovis, Pharmachemie Bv, Sagent Pharms Inc, Sandoz, Bristol, Bristol Myers, Bristol Myers Squibb, Azurity, Alembic, Amneal Pharms, Barr, Daito, Duramed Pharms Barr, Elite Labs Inc, Eugia Pharma, Lotus Pharm Co Ltd, Mylan, Strides Pharma Intl, Sun Pharm, and Zydus Pharms, and is included in fifty-three NDAs. There are seven patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Methotrexate sodium has three patent family members in three countries.

There are three drug master file entries for methotrexate sodium. Twenty-nine suppliers are listed for this compound.

Summary for METHOTREXATE SODIUM

International Patents:	3
US Patents:	7
Tradenames:	12
Applicants:	30
NDAs:	53
Drug Master File Entries:	3
Finished Product Suppliers / Packagers:	29
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	41
Patent Applications:	5,280
What excipients (inactive ingredients) are in METHOTREXATE SODIUM?	METHOTREXATE SODIUM excipients list
DailyMed Link:	METHOTREXATE SODIUM at DailyMed

Recent Clinical Trials for METHOTREXATE SODIUM

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Université de Sherbrooke	PHASE2
Region Skane	PHASE4
GlaxoSmithKline	PHASE4

See all METHOTREXATE SODIUM clinical trials

Pharmacology for METHOTREXATE SODIUM

Drug Class	Folate Analog Metabolic Inhibitor
Mechanism of Action	Folic Acid Metabolism Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for METHOTREXATE SODIUM

L01BA	Folic acid analogues
L01B	ANTIMETABOLITES
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

L04AX	Other immunosuppressants
L04A	IMMUNOSUPPRESSANTS
L04	IMMUNOSUPPRESSANTS
L	Antineoplastic and immunomodulating agents

US Patents and Regulatory Information for METHOTREXATE SODIUM

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pharmachemie Bv	METHOTREXATE SODIUM PRESERVATIVE FREE	methotrexate sodium	INJECTABLE;INJECTION	040843-004	Jan 11, 2010	AP	RX	No	No
Pharmacia And Upjohn	FOLEX	methotrexate sodium	INJECTABLE;INJECTION	087695-002	Apr 8, 1983		DISCN	No	No
Fresenius Kabi Usa	METHOTREXATE SODIUM	methotrexate sodium	INJECTABLE;INJECTION	040263-001	Feb 26, 1999	AP	RX	No	Yes

International Patents for METHOTREXATE SODIUM

Country	Patent Number	Title	Estimated Expiration
Spain	2726524
European Patent Office	2614814	Composition de méthotrexate (Methotrexate composition)
United Kingdom	201200192

Market Dynamics and Financial Trajectory for Methotrexate Sodium

Last updated: July 27, 2025

Introduction

Methotrexate sodium, a cornerstone in the management of autoimmune disorders and oncology, remains a critical pharmaceutical agent with a complex and evolving market landscape. Known primarily for treating rheumatoid arthritis, psoriasis, and certain cancers, methotrexate's clinical significance drives its sustained demand and influences market dynamics. As the pharmaceutical industry advances with novel therapies and biosimilars, understanding the current and projected financial trajectory of methotrexate sodium provides invaluable insights for stakeholders ranging from manufacturers to healthcare providers.

Global Market Overview

The global methotrexate market is characterized by steady growth, underpinned by the increasing prevalence of autoimmune diseases and cancers worldwide. According to Market Research Future (MRFR), the global autoimmune disease treatment market, which heavily incorporates methotrexate, is projected to reach USD 37 billion by 2027, growing at a compound annual growth rate (CAGR) of approximately 4% (2020–2027)[1]. This growth correlates directly with methotrexate's central role as a first-line disease-modifying antirheumatic drug (DMARD).

Injectable and oral formulations dominate the market, with injectables accounting for a significant share due to their efficacy in oncology settings. In developed regions like North America and Europe, methotrexate continues to be widely used, supported by established healthcare infrastructure and treatment guidelines favoring its use.

Market Drivers

Rising Prevalence of Autoimmune Diseases and Cancers

The increasing incidence of rheumatoid arthritis, psoriasis, and certain lymphomas sustains demand. The American College of Rheumatology reports that approximately 1.5 million Americans suffer from rheumatoid arthritis, with similar epidemiology observed globally[2]. Growing cancer cases further support the oncology segment where methotrexate remains a standard treatment, particularly for leukemias and lymphomas.

Cost-Effectiveness and Proven Efficacy

Methotrexate's longstanding clinical record, low cost, and proven efficacy make it an attractive choice for healthcare systems aiming to optimize budgetary constraints, thereby ensuring its continued utilization.

Patent Expiry and Biosimilar Entry

Patent expiration of brand-name methotrexate products has facilitated the entry of biosimilars, fostering price competition and expanding accessibility, especially in emerging markets. For instance, Teva's biosimilar methotrexate has gained approval in multiple jurisdictions, reducing prices and increasing adoption[3].

Technological Advances and Formulation Improvements

Innovations in drug delivery, such as targeted injectable formulations, improve patient compliance and reduce adverse effects, enhancing market sustainability.

Market Challenges

Emerging Biologic and Targeted Therapies

The influx of biologics and targeted small molecules for autoimmune diseases and cancers threaten methotrexate's dominance. Drugs like adalimumab and tofacitinib exhibit superior efficacy in some indications, potentially reducing methotrexate's share.

Safety and Toxicity Concerns

Long-term toxicity, including hepatotoxicity and marrow suppression, necessitates careful monitoring, which can limit usage in certain patient populations and impede market expansion.

Regulatory and Reimbursement Dynamics

Stringent regulatory standards and payer reimbursement policies influence drug accessibility and profitability. Variability across countries complicates global market forecasts.

Financial Trajectory and Future Outlook

Historical Revenue Performance

Global sales of methotrexate are estimated to range between USD 600 million to USD 1 billion annually, fluctuating with generic penetration and regional demand. The North American market produces approximately 50–60% of total revenues, reflecting high adoption rates.

Projected Growth Trends

In the next five years, the market is anticipated to grow at a CAGR of approximately 3–4%. Growth prospects are more pronounced in emerging markets like Asia-Pacific, where increasing healthcare infrastructure and affordability drive adoption. The Asia-Pacific region is expected to witness a CAGR of 5%–6%, driven by expanding autoimmune disease prevalence and evolving regulatory landscapes permitting biosimilar penetration.

Impact of Biosimilars and Generic Drugs

Entry of biosimilars is expected to exert downward pressure on prices, impacting revenue margins but expanding overall volume sales. Market leaders are strategizing to maintain profitability through diversified formulations and combination therapies.

Pipeline Developments and Industry Innovations

While no major novel formulations of methotrexate are currently in late-stage development, ongoing research into optimized delivery methods and combination regimens could prolong its market relevance. Additionally, technological advancements enhancing safety profiles may bolster long-term market stability.

Competitive Landscape

The industry comprises key players including Teva Pharmaceuticals, Mylan, Sandoz, and Apotex, all producing generic and biosimilar methotrexate. Strategic partnerships, licensing agreements, and regional market penetration efforts underpin competitive tactics. Large pharmaceutical firms are also investing in developing targeted therapies that could serve as alternatives, influencing the long-term market dynamics.

Regulatory and Legal Considerations

Regulatory agencies such as the FDA, EMA, and PMDA maintain rigorous standards for biosimilar approval, influencing market entry timelines and pricing strategies. Patent litigations around formulations and manufacturing processes occasionally divert market sales and impact financial projections.

Conclusion: Navigating Future Market Dynamics

The market for methotrexate sodium remains robust but faces significant evolution driven by biosimilar proliferation, therapeutic innovation, and regulatory shifts. Stakeholders should monitor regional adoption patterns, biosimilar regulatory updates, and emerging treatment algorithms to optimize investment strategies.

---

Key Takeaways

• Steady Global Demand: The continuing rise in autoimmune and cancer conditions sustains consistent demand for methotrexate.
• Biosimilar Expansion: Entry of biosimilars at competitive prices is expected to enhance accessibility but exert pressure on profit margins.
• Emerging Markets: Asia-Pacific and other emerging regions present lucrative growth opportunities due to increasing healthcare access.
• Competitive Pressures: Newer biologic agents and targeted therapies could diminish methotrexate’s market share in certain indications.
• Long-Term Outlook: Despite challenges, methotrexate's clinical utility, cost-effectiveness, and ongoing innovations position it for moderate growth through 2028.

---

FAQs

1. How will biosimilar entry impact methotrexate's market revenue?
Biosimilars typically reduce drug prices, increasing volume sales but decreasing revenue per unit. This dynamic can lower overall profit margins for original manufacturers while expanding patient access and total market size.

2. Are there any new formulations or delivery methods for methotrexate in development?
Current research focuses on optimizing administration routes, such as subcutaneous injections and targeted delivery systems, to improve safety and compliance. However, no groundbreaking formulations are close to regulatory approval presently.

3. Which regions present the highest growth potential for methotrexate?
Emerging markets in Asia-Pacific, Latin America, and parts of Africa are poised for rapid growth owing to expanding healthcare infrastructure, increased disease prevalence, and biosimilar adoption.

4. How do safety concerns affect methotrexate’s market sustainability?
Toxicity risks necessitate careful patient monitoring, which can restrict usage in certain cases. However, adherence to safety guidelines maintains its role as a first-line treatment, ensuring steady demand.

5. What strategies can manufacturers adopt to remain competitive?
Investing in biosimilar development, expanding regional presence, improving formulations for better safety and compliance, and collaborating with healthcare systems can bolster market position.

---

References

[1] Market Research Future. (2020). Global Autoimmune Disease Treatment Market Analysis.
[2] American College of Rheumatology. (2019). Rheumatoid Arthritis Prevalence Data.
[3] Teva Pharmaceuticals. (2021). Biosimilar Methotrexate Approvals and Market Access.